Related Experiment Video

Updated: Aug 8, 2026

Ferric Chloride-induced Murine Thrombosis Models
10:37

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

Recent advance in antiplatelet therapy: the mechanisms, evidence and approach to the problems

Hisanori Horiuchi1

  • 1Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan. horiuchi@kuhp.kyoto-u.ac.jp

Annals of Medicine
|May 25, 2006
PubMed

Insights

Identifying patients resistant to antiplatelet therapy is crucial for preventing cardiovascular events. This review explores alternative antiplatelet drugs for patients with aspirin or thienopyridine resistance.

Area of Science:

  • Cardiology
  • Pharmacology
  • Thrombosis

Background:

  • Antiplatelet therapy is vital for preventing ischemic cardiovascular diseases and thrombotic events post-coronary stent implantation.
  • Aspirin and thienopyridines (P2Y12 inhibitors) are established antiplatelet agents.
  • Platelet resistance to these drugs is linked to elevated cardiovascular risk.

Purpose of the Study:

  • To review current challenges in antiplatelet therapy, focusing on drug resistance.
  • To discuss alternative antiplatelet agents for patients with aspirin or thienopyridine resistance.
  • To explore the mechanisms, evidence, and clinical approaches for managing antiplatelet resistance.

Main Methods:

  • Literature review of clinical evidence on antiplatelet drugs.
  • Analysis of mechanisms of action for various antiplatelet agents.
  • Discussion of clinical implications and management strategies for antiplatelet resistance.

Main Results:

  • Platelet resistance to aspirin and thienopyridines poses a significant clinical problem.
  • Alternative antiplatelet drugs show promise for patients with resistance.
  • Understanding drug resistance mechanisms is key to optimizing therapy.

Conclusions:

  • Effective identification and management of antiplatelet resistance are essential for improving patient outcomes.
  • Alternative antiplatelet agents offer viable options for resistant patient populations.
  • Further research into novel antiplatelet mechanisms and resistance pathways is warranted.

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...